1-[4-[(1-Oxo-2-propen-1-yl)oxy]butyl] pentanedioate | 139486-57-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-[4-[(1-Oxo-2-propen-1-yl)oxy]butyl] pentanedioate
• 英文别名: 5-oxo-5-(4-prop-2-enoyloxybutoxy)pentanoic acid
• CAS: 139486-57-0
• 化学式: C₁₂H₁₈O₆
• 分子量: 258.27
• InChiKey: BRDFRQGELKSNJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  89.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• ESTER GROUP CONTAINING LIQUID CRYSTALS FOR OPTICAL OR ELECTRO OPTICAL DEVICES
  申请人：Eckert Jean Francois

  公开号：US20120114907A1

  公开（公告）日：2012-05-10

  The invention relates to polymerisable liquid crystals compound (I) having a liquid crystalline phase and to liquid crystalline compositions comprising compounds (I), their use as birefringence layer.

  该发明涉及具有液晶相的可聚合液晶化合物(I)，以及包含化合物(I)的液晶组合物，它们可用作双折射层。
• Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use
  申请人：Johnson & Johnson Clinical Diagnostics, Inc.

  公开号：EP0462644A1

  公开（公告）日：1991-12-27

  Biologically active reagents are prepared from particles of copolymers having highly reactive carboxy or equivalent groups. The reagents are prepared by covalently attaching biologically active substances, for example antibodies, to the particles, directly or indirectly through highly reactive carboxy groups on the particle surface. These reagents are used to advantage in analytical elements, methods for the detection of specific binding ligands (such as immunological species) and immunoassays, and in purification methods as affinity chromatography reagents.

  生物活性试剂由具有高活性羧基或等效基团的共聚物颗粒制备而成。制备试剂的方法是将生物活性物质（如抗体）直接或间接地通过颗粒表面的高活性羧基共价连接到颗粒上。这些试剂可用于分析元件、检测特定结合配体（如免疫物种）的方法和免疫测定，也可作为亲和层析试剂用于纯化方法。
• Ester group containing compounds for optical or electro optical devices
  申请人：Rolic AG

  公开号：EP2272937A1

  公开（公告）日：2011-01-12

  The invention relates to compounds (I): wherein         R2=a----Y⁅R1]t wherein: "- - - -" the interrupted line in R1 symbolizes the linkage to compound (I) or R2 and "- - - -" the interrupted line in R2 symbolizes the linkage to compound (I) , and t   represents 0 or 1, Y   represents -O(CO)-, -COO-, -O(CO)-O-, or a single bond, Y   represents OH, COOH, COOC1-C6alkyl, halogen, and wherein -(C1-X1)n1-C2-(X2-C3)n2-   is a divalent core, wherein; C1, C2 and C3   are in each case independently substituted or unsubstituted non- aromatic, aromatic, carbocyclic or heterocyclic groups; X1and X2   each independently represent -O-, -S-, -NH-, -N(CH3)-, -N=N-, -CH=N- , -N=CH-, -CO-C=C-, -CH(OH)-, -CO-, -CH2O-, -OCH2-, -CH2(CO)-, -SO-, -CH2(SO)-, -SO2-, -CH2(SO2)-, -COO-, -O(CO)-, -O(CO)-O-, -S-CO-, -CO-S-, -SOO-, -OSO-, -CH2-CH2-, -CH2-CH2-CH2-CH2-, -OCH2-, -CH2O-, -CH=CH-, -C≡C- or a single bond; n1 and n2   are integers, each independently having a value from 0 to 4, SP1, SP2 represent independently from each other substituted or unsubstituted divalent group, Z   represents hydrogen, C1-C6alkyl or halogen, with the proviso that the compounds of the following formula is excluded from the scope of this invention Further, the present invention relates to liquid crystalline compositions comprising compounds (I) and use their as birefringence layers.

  本发明涉及化合物 (I)： 其中 R2=a----Y⁅R1]t 其中 R1 中的间断线"- - - "表示与化合物 (I) 或 R2 的连接，以及 R2 中的"- - - - "表示与化合物 (I) 的连接，以及 t 代表 0 或 1、 Y 代表-O(CO)-、-COO-、-O(CO)-O-或单键、 Y 代表 OH、COOH、COOC1-C6 烷基、卤素，其中 -(C1-X1)n1-C2-(X2-C3)n2-是二价核心，其中； C1、C2 和 C3 在每种情况下都是独立的取代或未取代的非芳香、芳香、碳环或杂环基团； X1和X2各自独立地代表-O-、-S-、-NH-、-N(CH3)-、-N=N-、-CH=N-、-N=CH-、-CO-C=C-、-CH(OH)-、-CO-、-CH2O-、-O -、-CH2(CO)-、-SO-、- (SO)-、-SO2-、- (SO2)-、-COO-、-O(CO)-、-O(CO)-O-、-S-CO-、-CO-S-、-SOO-、-OSO-、- - -、- - -、-O -、- -、-CH=CH-、-C≡C- 或单键； n1 和 n2 为整数，各自独立地具有 0 至 4 的值、 SP1、SP2 各自独立地代表取代或未取代的二价基团、 Z 代表氢、C1-C6 烷基或卤素，但下式化合物不在本发明范围内 此外，本发明还涉及包含化合物（I）的液晶组合物，并将其用作双折射层。
• Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to caboxylated particles & a kit containing same
  申请人：Johnson & Johnson Clinical Diagnostics, Inc.

  公开号：EP0462670B1

  公开（公告）日：1996-08-21
• Biologically active reagent, analytical element and methods for use of the reagent
  申请人：Johnson & Johnson Clinical Diagnostics, Inc.

  公开号：EP0468585B1

  公开（公告）日：1995-11-08